Pharmacogenomics of HIV Therapy - Atazanavir Bilirubin-related Side Effects
Biomarkers (6)
- atv_m12_bilirubin - Bilirubin level at 12 months on Atazanavir (phv00367721.v1.p1)
- atv_m12_hb - Hemoglobin level at 12 months on Atazanavir (phv00367722.v1.p1)
- bl_bilirubin - Baseline bilirubin level (phv00367717.v1.p1)
- bl_hb - Baseline Hemoglobin level (phv00367718.v1.p1)
- last_bilirubin - Bilirubin level at last visit (phv00367719.v1.p1)
- last_hb - Hemoglobin level at last visit (phv00367720.v1.p1)
Demographics (5)
- age_at_last_atv_stop - Age at last ATV discontinuation (phv00367707.v1.p1)
- age_at_med_start - Age at ART initiation (phv00367689.v1.p1)
- age_enrolement - Age at enrollment to clinic (phv00367699.v1.p1)
- age_last_visit - Age at last clinic visit (phv00367703.v1.p1)
- sex - Self-reported sex (phv00367688.v1.p1)
Medications (7)
- atazanavir - Treatment with Atazanavir (phv00367709.v1.p1)
- azt - NRTI : Zidovudine (phv00367690.v1.p1)
- d4t - NRTI : Stavudine (phv00367692.v1.p1)
- ddi - NRTI : Didanosine (phv00367696.v1.p1)
- ftc - NRTI : Emtricitabine (phv00367695.v1.p1)
- lami - NRTI : Lamivudine (phv00367691.v1.p1)
- tdf - NRTI : Tenofovir (phv00367694.v1.p1)
Race and Ethnicity (1)
- race - Race (phv00367701.v1.p1)
Other (35)
- abc - NRTI : Abacavir (phv00367693.v1.p1)
- AFFECTION_STATUS - Case - control status of the subject (phv00367677.v1.p1)
- ANALYTE_TYPE - Analyte Type (phv00367726.v1.p1)
- art_before_first_visit - Previous ART exposure before first clinic visit (phv00367708.v1.p1)
- art_naive - Art (Antiretroviral therapy) naive (phv00367702.v1.p1)
- atv_dc_icterus - Atazanavir discontinuation for icterus (phv00367724.v1.p1)
- ATV_DURATION - Duration of ATV treatment in days (phv00367686.v1.p1)
- atv_perm_dc - ATV permanent discontinuation (phv00367698.v1.p1)
- atv_perm_dc_m12 - Atazanavir discontinuation at 12 months 1= Yes 0=No (phv00367715.v1.p1)
- atv_perm_dc_m6 - Atazanavir discontinuation at 6 months 1=Yes 0=No (phv00367714.v1.p1)
- causes_numb - Causes of ATV discontinuation (phv00367684.v1.p1)
- CONSENT - Consent group as determined by DAC (phv00367674.v1.p1)
- dc_cause - Recoding of causes of ATV discontinuation (phv00367685.v1.p1)
- dc_cause_final - Final cause of ATV discontinuation (phv00367687.v1.p1)
- fup_1st_atv_regimen_day - Duration 1st ATV regimen in days (phv00367706.v1.p1)
- fup_1st_regimen_day - Duration of 1st regimen (phv00367711.v1.p1)
- fup_art_total_day - Total duration of ART (phv00367713.v1.p1)
- fup_atv_total_day - Total duration of treatment with Atazanavir (phv00367710.v1.p1)
- fup_day - Total follow-up in days (phv00367704.v1.p1)
- genotype - Recoded genotype (phv00367697.v1.p1)
- lost_fup_m12 - Lost follow-up at 12 months 1=Yes, 0=No (phv00367716.v1.p1)
- regimen_nbr - Number of different ART regimens (phv00367712.v1.p1)
- SAMPLE_ID - Sample ID (phv00367679.v1.p1)
- SAMPLE_ID - De-identified Sample ID (phv00367725.v1.p1)
- SAMPLE_SOURCE - Source repository where samples originate (phv00367680.v1.p1)
- SAMPLE_USE - Sample Use (phv00367682.v1.p1)
- SOURCE_SAMPLE_ID - Sample ID used in the Source Repository (phv00367681.v1.p1)
- SOURCE_SUBJID - Subject ID used in the Source Repository (phv00367676.v1.p1)
- SUBJ_SOURCE - Source repository where subjects originate (phv00367675.v1.p1)
- SUBJECT_ID - De-identified Subject ID (phv00367683.v1.p1)
- SUBJECT_ID - Subject ID (phv00367673.v1.p1)
- SUBJECT_ID - Subject ID (phv00367678.v1.p1)
- time - Time analysis - total time with treatment (phv00367723.v1.p1)
- yr_enrolement - Year of enrollment (phv00367700.v1.p1)
- yr_last_visit - Year of last clinic visit (phv00367705.v1.p1)